The influence of nitric oxide on in vivo human skeletal muscle properties.
We have investigated the action of exogenous nitric oxide (NO) on the strength and contractile properties of human skeletal muscle working in vivo. Maximum isometric voluntary contraction force (MVC) of the quadriceps was measured and superimposed electrical stimulation was used to estimate the level of activation and 'true maximum force' (TMF). Force-frequency relationships were determined to assess changes in contractile properties of the muscle. Subjects in the experimental group (E, n=10) were measured before and during two separate periods of treatment with different doses of glyceryl trinitrate, a NO donor, delivering 100 (GTN100) or 200 (GTN200) microg h-1 as a trans-dermal patch. A control group (C, n=6) was measured during two similar periods whilst taking an oral placebo. There was a significant increase in strength with GTN200 (MVC: +5. 15%; TMF: +3.87%). There was no change in the strength of group C. There was a trend towards reduced forces at submaximal frequencies with GTN administration but the most notable change was a decline in twitch force (approximately 12%, P < 0.05) with GTN100 treatment and this remained depressed throughout the study. No changes were seen in the contractile properties of the control group C. The present results show that GTN treatment increased maximum voluntary strength but decreased twitch tension. The time course and dose-response characteristics indicate that these are two separate actions of NO on human muscle working in vivo.
Folland
J P
JP
School of Sport and Exercise Sciences, University of Birmingham, UK.
Maas
H
H
Jones
D A
DA
D000328:Adult; D004558:Electric Stimulation; D005260:Female; D006801:Humans; D007537:Isometric Contraction / Q000187:drug effects*; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000502:physiology*; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000008:administration & dosage*; D005996:Nitroglycerin / Q000008:administration & dosage*; D014665:Vasodilator Agents / Q000008:administration & dosage*; D014836:Volition / Q000502:physiology
D020030:Nitric Oxide Donors; D014665:Vasodilator Agents; D009569:Nitric Oxide; D005996:Nitroglycerin